200950794 九、發明說明： 【發明所屬之技術領域】 本發明係有關於一種抑制癌症的桑黃三寶複方，主要 用於抑制癌細胞的生長，利用中草藥的萃取物以適當比例 混合來達到抑制癌細胞生的功效，實為一充分符合產業利 用性之方法。 【先前技術】 按’習用之「一種治療廣泛性癌症中藥複方」如中華 ❹民國專利申請案第0 Θ 3 1 0 1 Θ 0 4號，一種治療淋巴 結關係型癌症的中藥複方，係包含有黨蔘（c〇d〇n〇psis200950794 IX. INSTRUCTIONS: [Technical Field] The present invention relates to a compound of Mulberry Sambo which inhibits cancer, and is mainly used for inhibiting the growth of cancer cells, and extracting the extracts of Chinese herbal medicines at appropriate ratios to inhibit cancer cells The effect of life is actually a method that fully meets the industrial applicability. [Prior Art] According to the 'conventional compound of Chinese medicine for treating a wide range of cancers', such as the Chinese Patent Application No. 0 Θ 3 1 0 1 Θ 0 4, a Chinese herbal compound for treating lymph node-related cancer, including a party蔘(c〇d〇n〇psis
Pilosula )、黃芪（Astragalus membranaceus )、薏苡仏 (Coix Lacyma-Jobi )、山佩蘭（Eupatorium japonicum ) 、橘皮（Citrus reticulata )、爵床（Rostellularia procumbens )、夏枯草（Prunella Vulgaris )、涼粉草 (Mesons chinensis )、槐子（Gardenia jasminoides)、 φ 連翹（Forsythia suspensa)、赤勺（Paeonis Veitchii ) 、蛾(Eupolyphaga sinensis)、白花蛇舌草（Hedotis diffusa )、拉板歸（Polygonum per foliatum)、山豆根 (Sophora tonkinensis )、木槿皮（Hibiscus syiacus ) 、天南星（Arisaema heterophyllum )、半邊蓮（Lobelia chinensis)、白蔽（Ampelopsis joponica )、漏蘆 (Rhaponticum uniflorum )、石葦（Pyrrosia sheareri ) 、乳香（Boswellig carterii)、沒藥（Commiphora Myrrha )、蚤休（Paris polyphylla )、敗醬（Patrinia 200950794Pilosula ), Astragalus membranaceus, Coix Lacyma-Jobi, Eupatorium japonicum, Citrus reticulata, Rostellularia procumbens, Prunella Vulgaris, Mesons Chinensis ), Gardenia jasminoides, φ Forsythia suspensa, Paeonis Veitchii, Eupolyphaga sinensis, Hedotis diffusa, Polygonum per foliatum, Bean Root (Sophora tonkinensis), Hibiscus syiacus, Arisaema heterophyllum, Lobelia chinensis, Ampelopsis joponica, Rhaponticum uniflorum, Pyrrosia sheareri, Boswellig Carterii), Commiphora Myrrha, Paris polyphylla, Sauce (Patrinia 200950794)
Villosa )、白！（ Angelica dehurica )、射幹 (Belamcanda chinensis)、蒲公英（Taraxacum mongolicum )、螺舉草（Lemmaph ylium microphyyilum presl )皂爽（Gleditsia sinensis )、獨活（Angelica biserrate)、麻黃（Ephedrasinica)、升麻（Cimicifuga foetida )等藥物。 ❹Villosa), white! ( Angelica dehurica ), Belamcanda chinensis, Taraxacum mongolicum, Lemmaph ylium microphyyilum presl, Gleditsia sinensis, Angelica biserrate, Ephedrasinica, Cimicifuga Cimicifuga foetida) and other drugs. ❹
有鑑於上述之藥物種類，本發明人認為其有急待改進 之必要’乃思及改良創作之意念，及其一貫秉持具有之優 良設計理念，針對既有之缺失加以改良，經多方設計探討 並多次修正改良，終乃有本發明抑制癌症的桑黃三寶複方 ’係為一充分符合實用進性之設計。 【發明内容】 引以習用之一種治療廣泛性癌症的中藥方，其有諸多 不同的中草藥配方，依據各種不同的藥性須相互搭配，但 有副作用的機率也相對提高’因應本發明抑制癌症的桑i 寶複方作為其改良之技術，本發明優點在於草藥的配= 類較少，故產生副作用的機率相對降低，可使中草藥 性充分發會以達到最佳的抑制效果者。 y、、樂 本發明之抑制癌症的桑黃三寶複方，〔請參 〕由下述中草藥萃取粉末所相混合而成的複方，其 人參皂甙提取物（Ginsenoside) ( 1 )、牛摄—=由 末（Antrodm Camphorata ) ( 2 )、桑黃子實體粉末 Pheinus Linteus ) ( 3 )所組成。 ”（ 【實施方式】 200950794 混合抑制癌症的七寶根複方時，首先〔請參閱第一圖 〕其中草藥之混合比例（以7 0 0 0 mg)為例，人參皂武 提取物（Ginsenoside) (1)於 7〇〇〇1^中佔15〇〇 mg約為2 1 · 5 %、牛樟芝菌絲體粉末（Antrodia 以师匕〇1'9^)(2)於7 000111运中佔2500呢約為3 5 · 7%、桑黃子實體粉末（pheinus Linteus ) ( 3 )於 7 0 0 Omg中佔3 〇 〇 〇mg約為4 2 · 8%，以上述之混In view of the above-mentioned types of drugs, the inventors believe that they have the urgent need to improve the idea of thinking and improving the creation, and consistently adhere to the excellent design concept, to improve the existing defects, and to explore and design through multiple parties. The modification and improvement have been repeated many times, and the invention has the design of the Sanghuang Sanbao compound which inhibits cancer in the present invention. SUMMARY OF THE INVENTION A traditional Chinese medicine for treating a wide range of cancers has many different Chinese herbal medicine formulas, which are matched with each other according to various medicinal properties, but the probability of side effects is relatively increased. i Baofufang as its improved technology, the advantage of the invention is that the herbal medicine has fewer formulas, so the probability of side effects is relatively reduced, and the Chinese herbal medicine can be fully developed to achieve the best inhibitory effect. y, Leben's anti-cancer mulberry three treasure combination, [please refer to] the combination of the following Chinese herbal extract powder, the ginsenoside extract (Ginsenoside) (1), cattle photo -= by It is composed of Antrodm Camphorata (2) and Pheinus Linteus (3). (Embodiment) 200950794 When combining the Qibaogen compound for cancer suppression, first (see the first figure), the mixture ratio of the herbs (in the case of 700 mg), Ginsenoside (Ginsenoside) 1) In the 7〇〇〇1^, 15〇〇mg is about 2 1 · 5 %, Antrodia camphorata mycelium powder (Antrodia is 1匕〇9^) (2) in 2 000111, which accounts for 2500. About 3 5 · 7%, pheinus Linteus ( 3 ) accounted for 3 · mg of about 4 2 · 8% in 700 mg, mixed with the above
合比例相互混合者。 將抑制癌症的桑黃三寶複方針對下列癌症細胞的抑制 其生長結果，〔請參閱第二圖〕本發明對於乳癌細胞的抑 制生長，針對MCF10A、MCF-7、MDA-MB-231三種乳癌細胞 ’經實驗結果發現本發卿於Μα?_7此祕癌細胞的最佳 抑制效果可達約5 Q % ’〔請參閱第三圖〕本發明對於肝 癌、.、田胞的抑制生長，針對卿…打、Η印㈣⑵、 Huh7四種肝癌細胞’經實驗結果發現本發明對於_ 種肝癌細胞的最佳抑制效果可達約為3〇%，〔請參閱第 =圖〕本發明對於肺癌細胞的抑制生長，針對cn 谅。1兩ί肺癌細胞’經實驗結果發現本發明對於兩種肺 癌細胞的最佳抑制钕 那 〕本發明⑽均可達約5〇%，〔請參閱第五圖 ^ '癌細胞的抑制生長，針對AGS此種胃癌細 胞，經實驗結果發理士 ^ 丹塯細 抑制效果達約1〇^發明對於脱此種胃癌細胞的最佳 頭癌細胞的抑制生#°’〔請參閱第六圖〕本發明對於子宮 驗結果發現本發明對2對_此種子㈣癌細胞，經實 ;Hela此種子宮頸癌細胞的最佳的抑 7 200950794 制效果可達約20%’ 〔請參 癌細胞的抑制生長，針訝SW48〇 圖〕本發明對於大腸 結果發現本發明對於S_此種腸癌細胞’經實驗 果為達約議，〔請參閱第4腸f田胞的最佳抑制效 ^ 圖〕本發明對於血癌細腧 的抑制生長，針對NB4此種血癌細胞，、·、胞 對於血癌細胞的抑制生長無明顯的抑制效&發明Proportionately mixed with each other. The Sanghuang Sanbao compound which inhibits cancer inhibits the growth result of the following cancer cells, [see the second figure] The present invention inhibits growth of breast cancer cells, and targets three breast cancer cells MCF10A, MCF-7, and MDA-MB-231 The experimental results show that the best inhibitory effect of Benfaqing on Μα?_7 this secret cancer cell can reach about 5 Q% '[See the third figure] The present invention inhibits the growth of liver cancer, . It has been found that the best inhibitory effect of the present invention on the liver cancer cells of the present invention is about 3〇%, [see Fig. = Fig. 4] inhibition of lung cancer cells by the present invention. Growing, for cn forgive. 1 two lung cancer cells 'experimental results show that the optimal inhibition of the two lung cancer cells of the present invention can be about 5 % by the present invention (10), [see the fifth figure ^ 'the growth inhibition of cancer cells, AGS such gastric cancer cells, the experimental results of the hairy ^ 塯 塯 塯 塯 塯 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明 发明For the uterus test results, it was found that the present invention has two pairs of _ this seed (four) cancer cells, and the best effect of this kind of cervical cancer cells of Hela can reach about 20%' [see cancer cell growth inhibition, The present invention is found in the present intestine for the results of the large intestine. The present invention is for the experimental results of S_ such intestinal cancer cells, [see the best inhibitory effect of the fourth intestinal field]. For the growth inhibition of blood cancer, there is no obvious inhibitory effect on the growth inhibition of blood cancer cells by NB4.
症的==細Τ結果，經實驗結果發現抑制癌 的對乳肝癌、肺癌均有約30心上 心上的抑制==乳癌、肺癌的抑‘制效果可達約5 0 於权r上所述’當知本發明具有新酿，且本發明未見之 '可刊物，當符合專利法第2 1、2 2條之規定。The result of the disease == fine sputum, the results of the experiment found that the inhibition of cancer on breast cancer, lung cancer have about 30 mental heart inhibition == breast cancer, lung cancer, the effect of inhibition can reach about 50 The description of 'the invention has a new brewing, and the invention can not be seen as a publication, when it meets the requirements of Articles 21 and 22 of the Patent Law.
At唯以上所述者，僅為本發明之一較佳實施例而已，當 圍=以之限定本發明之範圍。即大凡依本發明申請專利範 所作之均等變化與修飾，皆應仍屬本發明專利涵 圍内。 粑 8 200950794 【圖式簡單說明】 第一圖：係本發明之配方比例示意圖 第二圖：係本發明之乳癌細胞實驗曲線示意圖 第三圖：係本發明之肝癌細胞實驗曲線示意圖 第四圖：係本發明之肺癌細胞實驗曲線示意圖 第五圖：係本發明之胃癌細胞實驗曲線示意圖 第六圖：係本發明子宮頸癌細胞實驗曲線示意圖 第七圖：係本發明之大腸癌細胞實驗曲線示意圖 第八圖：係本發明之血癌細胞實驗曲線示意圖 【主要元件符號說明】 1 人參皂戒提取物（Ginsenoside ) 2 牛樟芝菌絲體粉末（Antrodia Camphorata ) 3 桑黃子實體粉末（Pheinus Linteus ) 9At least the above description is only a preferred embodiment of the invention, and is intended to limit the scope of the invention. That is, the equivalent changes and modifications made by the applicant in accordance with the patent application of the present invention should remain within the scope of the present invention.粑8 200950794 [Simple description of the diagram] The first diagram is a schematic diagram of the formulation ratio of the present invention. The second diagram is a schematic diagram of the experimental curve of the breast cancer cell of the present invention. The third diagram is the schematic diagram of the experimental curve of the liver cancer cell of the present invention: Fig. 5 is a schematic view showing the experimental curve of the lung cancer cell of the present invention. Fig. 6 is a schematic view showing the experimental curve of the gastric cancer cell of the present invention. Fig. 7 is a schematic view showing the experimental curve of the cervical cancer cell of the present invention. Figure 8: Schematic diagram of the experimental curve of blood cancer cells of the present invention [Key element symbol description] 1 Ginsenoside extract 2 Antrodia Camphorata 3 Pheinus Linteus 9